Oakbrook Investments LLC lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,888 shares of the company’s stock after selling 200 shares during the quarter. Oakbrook Investments LLC’s holdings in IDEXX Laboratories were worth $1,540,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Pearl River Capital LLC bought a new stake in IDEXX Laboratories during the 4th quarter valued at about $28,000. Sontag Advisory LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $79,000. Quantamental Technologies LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $92,000. Ipswich Investment Management Co. Inc. purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $124,000. Finally, ETF Managers Group LLC increased its position in IDEXX Laboratories by 15.8% during the 4th quarter. ETF Managers Group LLC now owns 682 shares of the company’s stock valued at $127,000 after purchasing an additional 93 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.
A number of research analysts have commented on the stock. BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 target price on the stock in a research report on Friday, May 3rd. Finally, Canaccord Genuity raised their target price on shares of IDEXX Laboratories from $255.00 to $260.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. IDEXX Laboratories has an average rating of “Buy” and a consensus price target of $253.50.
Shares of IDEXX Laboratories stock traded up $1.61 on Friday, reaching $247.83. The stock had a trading volume of 630,407 shares, compared to its average volume of 469,650. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81. IDEXX Laboratories, Inc. has a 1 year low of $176.11 and a 1 year high of $256.22. The company has a market cap of $21.32 billion, a P/E ratio of 58.18 and a beta of 0.97.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.04 by $0.13. IDEXX Laboratories had a net margin of 17.33% and a return on equity of 354,783.84%. The firm had revenue of $576.06 million for the quarter, compared to the consensus estimate of $575.04 million. During the same quarter in the previous year, the firm earned $1.01 EPS. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 4.82 EPS for the current fiscal year.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Recommended Story: Relative Strength Index
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.